KR20210086662A - Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 - Google Patents
Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 Download PDFInfo
- Publication number
- KR20210086662A KR20210086662A KR1020217015632A KR20217015632A KR20210086662A KR 20210086662 A KR20210086662 A KR 20210086662A KR 1020217015632 A KR1020217015632 A KR 1020217015632A KR 20217015632 A KR20217015632 A KR 20217015632A KR 20210086662 A KR20210086662 A KR 20210086662A
- Authority
- KR
- South Korea
- Prior art keywords
- msc
- leu
- aoah
- ser
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752000P | 2018-10-29 | 2018-10-29 | |
| US62/752,000 | 2018-10-29 | ||
| PCT/CA2019/051526 WO2020087160A1 (en) | 2018-10-29 | 2019-10-29 | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210086662A true KR20210086662A (ko) | 2021-07-08 |
Family
ID=70462996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217015632A Ceased KR20210086662A (ko) | 2018-10-29 | 2019-10-29 | Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220010281A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3874029B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7372982B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210086662A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166729A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019370629A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2962812T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282820A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103509RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020087160A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302060A (en) * | 2020-10-16 | 2023-06-01 | Ottawa Hospital Res Inst | Cell-based therapy for viral diseases |
| CN116570711A (zh) * | 2022-12-21 | 2023-08-11 | 上海交通大学医学院附属第九人民医院 | 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用 |
| WO2026101889A2 (en) * | 2024-11-06 | 2026-05-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Acyloxyacyl hydrolase and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929604A (en) * | 1986-05-28 | 1990-05-29 | Board Of Regents, The University Of Texas System | Lipopolysaccharides of reduced toxicity and the production thereof |
| US5281520A (en) * | 1990-09-12 | 1994-01-25 | Zymogenetics, Inc. | Method for producing acyloxyacyl hydrolase |
| CN101378764A (zh) * | 2005-12-09 | 2009-03-04 | 贝勒研究院 | 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测 |
| JP2011528566A (ja) * | 2008-07-21 | 2011-11-24 | コンプジェン リミティッド | アンジオポエチン由来ペプチド |
| GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
| JP2012529895A (ja) * | 2009-06-19 | 2012-11-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗egfr抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法 |
| EP2626369A1 (en) * | 2011-11-24 | 2013-08-14 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Engineered mesenchymal stem cells and their therapeutic use |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| RU2658490C2 (ru) * | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| CA2928852A1 (en) * | 2013-11-01 | 2015-05-07 | Regeneron Pharmaceuticals, Inc. | Angiopoietin-based interventions for treating cerebral malaria |
| WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| KR102213527B1 (ko) * | 2014-06-30 | 2021-02-09 | 타이제닉스, 에스.에이.유. | 패혈증 치료용 중간엽 기질세포 |
| PL3242933T3 (pl) * | 2015-01-08 | 2019-08-30 | Apceth Gmbh & Co. Kg | Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat) |
| CA3172801A1 (en) * | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| CN108430480B (zh) * | 2015-09-15 | 2022-08-02 | 康干细胞生物科技有限公司 | 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物 |
-
2019
- 2019-10-29 EP EP19878837.4A patent/EP3874029B1/en active Active
- 2019-10-29 JP JP2021547607A patent/JP7372982B2/ja active Active
- 2019-10-29 KR KR1020217015632A patent/KR20210086662A/ko not_active Ceased
- 2019-10-29 AU AU2019370629A patent/AU2019370629A1/en not_active Abandoned
- 2019-10-29 CN CN201980071846.5A patent/CN113166729A/zh active Pending
- 2019-10-29 WO PCT/CA2019/051526 patent/WO2020087160A1/en not_active Ceased
- 2019-10-29 US US17/289,311 patent/US20220010281A1/en not_active Abandoned
- 2019-10-29 ES ES19878837T patent/ES2962812T3/es active Active
- 2019-10-29 SG SG11202103509RA patent/SG11202103509RA/en unknown
-
2021
- 2021-04-29 IL IL282820A patent/IL282820A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019370629A1 (en) | 2021-05-20 |
| WO2020087160A1 (en) | 2020-05-07 |
| EP3874029A1 (en) | 2021-09-08 |
| ES2962812T3 (es) | 2024-03-21 |
| EP3874029B1 (en) | 2023-08-30 |
| CN113166729A (zh) | 2021-07-23 |
| US20220010281A1 (en) | 2022-01-13 |
| IL282820A (en) | 2021-06-30 |
| EP3874029A4 (en) | 2022-08-03 |
| JP2022513379A (ja) | 2022-02-07 |
| JP7372982B2 (ja) | 2023-11-01 |
| CA3116196A1 (en) | 2020-05-07 |
| SG11202103509RA (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101992807B1 (ko) | 조직 재생을 유도하기 위한 펩티드 및 그의 이용 | |
| JP2023052475A (ja) | リソソーム障害を治療する方法 | |
| JP2020536510A (ja) | 細胞の遺伝子修飾のための非組込みdnaベクター | |
| CN1295617A (zh) | 血管生成因子-血管内皮细胞生长因子vegf的突变体 | |
| US20220323503A1 (en) | Methods and compositions for reconstituting microglia | |
| JP7372982B2 (ja) | Aoahを過剰発現する遺伝子組換え間葉系幹細胞及びその使用 | |
| CA3100262A1 (en) | Compositions and methods for haematopoietic stem cell transplantation | |
| US20080045699A1 (en) | Interleukin-1 Related Gene and Protein | |
| CN114452408A (zh) | 靶向枯否细胞用于治疗癌症的药物组合物 | |
| WO2003014340A2 (en) | Human histone deacetylase-related gene and protein hdac10 | |
| CA3116196C (en) | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof | |
| HK40057211B (en) | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof | |
| HK40057211A (en) | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof | |
| JP2023545539A (ja) | ウイルス性疾患のための細胞ベースの治療 | |
| US20030148952A1 (en) | Methods and materials for the recruitment of endothelial cells | |
| CN1307487A (zh) | 治疗内毒素血症的方法 | |
| US20230302054A1 (en) | Modification of t cells | |
| JP2025530652A (ja) | 遺伝子治療 | |
| JPWO2000008056A1 (ja) | 新規なポリペプチド、そのポリペプチドをコードするcDNA、およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |